SCHEMBL4889469

SCHEMBL4889469

CC[C@H]1CC(O)[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 7/20 0.65
LMNA P02545 9/20 0.60
CYP3A4 P08684 8/20 0.60
HSD17B10 Q99714 6/20 0.60
SERPINA6 P08185 6/20 0.60
MAPK1 P28482 6/20 0.60
TSHR P16473 5/20 0.60
MAPT P10636 5/20 0.60
NR3C1 P04150 4/20 0.60
PGR P06401 4/20 0.60
AR P10275 4/20 0.60
CYP19A1 P11511 4/20 0.60
SNCA P37840 4/20 0.60
GPBAR1 Q8TDU6 3/20 0.60
SIGMAR1 Q99720 3/20 0.60
CACNA1C Q13936 2/20 0.60
CYP51A1 Q16850 2/20 0.60
OR51E2 Q9H255 1/20 0.60
ALDH1A1 P00352 6/20 0.54
SMN1; SMN2 Q16637 6/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889466 1.00 SHBG (0.65) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL1899132 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL1901199 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL4104457 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL13752813 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL23711138 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL1899136 0.86 SHBG (0.71) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL6323169 0.83 CYP3A4 (0.69) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL572145 0.83 CYP3A4 (0.69) SHBGLMNACYP3A4HSD17B10SERPINA6
SCHEMBL13753014 0.82 SMN1; SMN2 (0.70) SHBGLMNACYP3A4HSD17B10SERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors UNIVERSITY OF EDINBURGH (GB) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors HSD11B1, HSD11B2, CYP11B1 SHBG 1208/4885LMNA 4376/4885CYP3A4 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.